Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis | Zendy

Emma GuttmanYassky | Zendy; Andrew Blauvelt | Zendy; Lawrence F. Eichenfield | Zendy; Amy S. Paller | Zendy; April W. Armstrong | Zendy; Janice Drew | Zendy; Ramanan Gopalan | Zendy; Eric L. Simpson | Zendy

Open Access

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

Author(s) -

Emma GuttmanYassky,

Andrew Blauvelt,

Lawrence F. Eichenfield,

Amy S. Paller,

April W. Armstrong,

Janice Drew,

Ramanan Gopalan,

Eric L. Simpson

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2020.0079

Subject(s) - eczema area and severity index , medicine , atopic dermatitis , placebo , randomized controlled trial , dermatology life quality index , adverse effect , clinical endpoint , clinical trial , gastroenterology , immunology , pathology , disease , alternative medicine

Interleukin 13 (IL-13) is a central pathogenic mediator driving multiple features of atopic dermatitis (AD) pathophysiology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research